News
ICYMI: Issues in AxSpA: Treatment Intensification, Pregnancy
Is MTX Safe in the Elderly? (12.1.2023)
Dr. Jack Cush reviews this past week's news and journal reports from RheumNow.com. Good news is that nearly 99% of adult rheumatology positions matched! But the challenge is that 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled in the 2024 NRMP match.
ICYMI: Do Probiotics Improve Psoriatic Arthritis?
Rheum Fellowship Slots Fill Up for 2024
Next generation JAK-inhibition strategies
MTX Toxicity in Older CKD Patients
When should we be starting therapy in GCA and PMR?
Here’s what will change my practice in Rheumatoid Arthritis
Withdraw DMARDS after remission?
The possibility of withdrawing DMARDs after patients achieve remission has been in our minds for a while. Yet when our patients ask whether it is a good idea to taper or stop their DMARD when they are doing well, most of us don’t have a black or white answer for them.
Race to the top: how high will treatment response rates in RA reach?
We have become accustomed to the 60/40/20% rule for the outcome of ACR 20/50/70 respectively for biologics and targeted synthetic DMARDs. When a new agent is launched, we look out for the treatment response with much anticipation if it will be higher or lower than the benchmark we expect.